Tag Archives: Syros Pharmaceuticals

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Syros Pharmaceuticals (NASDAQ: SYRS), Flexion Therapeutics (NASDAQ: FLXN) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Syros Pharmaceuticals (SYRS – Research Report), Flexion Therapeutics (FLXN – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report). Syros Pharmaceuticals (SYRS) H.C.

H.C. Wainwright Sticks to Its Hold Rating for Syros Pharmaceuticals (SYRS)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $6.02. According to TipRanks.com, Fein is

Oppenheimer Remains a Buy on Syros Pharmaceuticals (SYRS)

In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $11.00. The company’s shares closed last Monday at $6.02. According to TipRanks.com, Breidenbach is a

Cowen & Co. Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report). The company’s shares closed last Monday at $6.02. According to TipRanks.com, Nadeau is a 4-star analyst with an

Cowen & Co. Keeps a Buy Rating on Syros Pharmaceuticals (SYRS)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today. The company’s shares closed last Monday at $5.52, close to its 52-week low of $4.45. According to TipRanks.com, Nadeau is a 5-star

H.C. Wainwright Maintains a Hold Rating on Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $5.02, close to its 52-week low of $4.88. According